The week in health tech, explained in plain English.Get the free newsletter →
October 11, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Government

Newsom Defends Medicaid Spending on Housing and Food

By Healthcare Technology News ·

California is fighting to protect one of the country's most ambitious Medicaid experiments. Through its CalAIM initiative, the state uses Medicaid money to pay for non-medical services like housing support, food, and case management for its most expensive patients, betting that addressing social needs cuts costly hospital and emergency care over time, according to KFF Health News.

Republicans in Washington are calling that spending waste, fraud, and abuse as they hunt for Medicaid cuts. Gov. Gavin Newsom has voiced concern about losing federal funding, but says he is proud of the state's holistic approach to caring for its sickest residents.

The dispute is bigger than California. Many states have won federal waivers to fund social determinants of health, and a crackdown would ripple across the health plans, community organizations, and tech vendors built to deliver and track these benefits. The core question: whether Medicaid should pay for anything beyond traditional medical care, and who decides.

Sources

More in Government

Government

NIH Plans National Push on Personalized Cancer Vaccines

The NIH plans a December public-private partnership to accelerate development of personalized cancer vaccines, per a New York Times report.

Why it matters: A federally coordinated effort could accelerate a promising but fragmented field of custom cancer immunotherapies toward wider clinical use.

Government

White House Plans $100M STEM PhD Push as NIH Sheds Scientists

The Trump administration plans to put over $100 million into STEM PhD fellowships, announced at an Oct. 8 White House summit, even as the NIH loses scientists.

Why it matters: The PhD pipeline fuels biomedical research across hospitals and biotech, but new fellowship funding may not offset talent losses at the NIH.

Government

Stem Cell Advocates Eye FDA Opening Under RFK Jr.

Stem cell advocates hope the FDA will grant their unproven therapies legitimacy under RFK Jr., mirroring how peptides gained acceptance through the MAHA movement.

Why it matters: If regulatory politics rather than clinical evidence starts shaping FDA acceptance, it could reshape patient access and safety standards across emerging therapies.